AIN
Future of Cancer Therapy

Future of Cancer Therapy

location_on North West ,  United Kingdom

Please note:
Investing in early stage businesses involves risks, including illiquidity, lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio. This platform is targeted solely at investors who are sufficiently sophisticated to understand these risks and make their own investment decisions. Investors are encouraged to review and evaluate the investments and determine at their own discretion, the appropriateness of making the particular investment. The information on this website is provided for informational purposes only, but we cannot guarantee that the information is accurate or complete. We strongly encourage investors to complete their own due diligence with licensed professionals, prior to making any investment and will not offer any legal or tax advice.

Short Summary

ImmunoKey is making CAR T-cell therapies capable of effectively treating solid tumours. Our core CARKey platform achieves unmatched tumour targeting with built-in safety to protect healthy cells and enhanced CAR T-cell persistence and fitness.

Highlights

  • First-in-class CAR T for solid tumours with logic-gated precision
  • Targeting ovarian cancer with clear market and high unmet clinical need
  • Led by team with prior cell therapy spinout, scale, and exit experience
  • Strong IP position; patents filed and path to FTO established
  • £900K seed round open with EIS advance assurance

Overview

Target €1,000,000
Minimum €100
Investment Raised €225,000
Previous Rounds €900,000
Stage MVP/Finished Product
Investor Role Any

Ask a question
Got a question about this project?

Similar Projects